Executive Director, Early Differentiation & Pipeline, Global Medical Neuroscience

Working with Us
Challenging. Meaningful. Life-changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it. You’ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams. Take your career farther than you thought possible.

Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives. Read more: careers.bms.com/working-with-us.

The Executive Director, Early Differentiation & Pipeline (EDAP), Global Medical Neuroscience will lead the early‑stage medical strategy to differentiate pipeline assets and accelerate high‑value programs from discovery through key governance milestones. This role shapes integrated evidence strategies (clinical and real‑world), defines target product profiles (TPPs), advances biomarker/diagnostic and personalized care approaches, and drives cross‑functional portfolio decisions that maximize launch readiness, patient access, and long‑term lifecycle value across Neuroscience, with strategic alignment to Neuroscience portfolio.

The leader will steward external scientific engagement, research collaborations, and scientific communications. while leading and coaching a high‑performing Early Asset Medical team. The Executive Director, Global Medical Neuroscience EDAP, will lead a team of Medical Strategy leads and Medical Product Leads (MPLs) and reports directly to the SVP, Global Head of Medical Affairs, Neuroscience will be key part of the Medical Neuroscience leadership team. This role will focus specifically on early pipeline assets in Phase 1 and Phase 2 signal-seeking development, maintaining dynamic prioritization of assets in partnership with discovery and early development teams to ensure efforts are invested in the most promising assets.

Key Responsibilities

Early Pipeline Differentiation & Evidence Strategy

• Collaborate with Discovery, Early Development, Translational Research, and Early Transition Assets on biomarker/diagnostic strategies and personalized care approaches, with particular emphasis on neuroimaging technologies, digital endpoints, and companion diagnostics (CDx) as well as their potential clinical applicability/utility.

• Understand the role of biomarkers, neuroimaging, digital endpoints, and diagnostic platforms in determining treatments across neurological diseases and integrate this understanding into early program strategic approaches.

• Lead creation of early Integrated Evidence Plans (IEPs) that differentiate clinical endpoints and real‑world outcomes.

• Shape IEPs and CCF plans beyond regulatory minimums to address unmet needs. • Provide key input to define optimal Target Product Profiles (TPPs).

• Inform and accelerate governance decisions on priority programs to ensure maximum transformational clinical value is captured via Clinical Development Plans (CDP) and Integrated Evidence Plans (IEP).

• Represent medical perspective in business development and licensing activities.

• Make recommendations to research and clinical development teams based on external landscape and insights from scientific partnerships and external experts.

• Ensure deep local and stakeholder insights inform pipeline shaping.

Portfolio Shaping, Governance & Prioritization

• Drive cross‑functional shaping across Neuroscience portfolios.

• Deliver early‑program strategic assessments to prioritize transformational assets.

• Establish cross‑asset medical strategies maximizing lifecycle value and patient access.

• Maintain an ongoing dynamic prioritization of assets in partnership with discovery and early development teams to ensure efforts are invested in the most promising asset.

• Ensure global alignment of medical strategic priorities across the Medical Matrix.

Evidence Generation, Access & Operations.

• Partner with Medical Evidence Generation (MEG), Global Drug Development (GDD), Global Development Operations (GDO), Health Economics and Outcomes (HEOR), and